Group 1: Digital Innovation - The company is accelerating its transformation towards "smart pharmaceutical retail" through self-developed digital tools such as PDA, salary calculator, smart store inspection system, and "Yujian" intelligent recommendation system, enhancing service efficiency and customer experience [2] - In the supply chain, the company is optimizing inventory management using algorithm models and digital tools to reduce manual operations and speed up inventory turnover [2] - The company has launched the "Shuyuzhiyuan" risk control platform, utilizing big data models to comprehensively prevent operational risks [2] Group 2: Diversification and Product Development - The company is collaborating with Dashi and Wangwang to establish the "Dashi Shuyuyuan" pharmacy, which will offer a diverse range of products beyond pharmaceuticals, including OTC health products, baby formula, maternal and infant products, nutritional supplements, medical devices, and cross-border products [3] - In 2024, the company's self-owned product sales achieved a year-on-year growth of 9%, accounting for over 13% of total retail sales [3] Group 3: Financial Performance and Store Distribution - The company's asset-liability ratio is slightly higher than the industry average due to its short listing time and small scale of equity financing, with recent market expansion through acquisitions [3] - As of March 2025, the company operates a total of 8,916 stores across Shandong, Liaoning, Heilongjiang, Fujian, Henan, and Gansu provinces, including 4,353 direct-operated stores and 4,563 franchised stores [3]

Core Points - The company reported a total operating revenue of 9.57 billion yuan for 2024, representing a year-on-year increase of 4.13% [1][2] - The net profit attributable to shareholders was -189 million yuan, a significant decline from a profit of 133 million yuan in the previous year, marking a decrease of 241.90% [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -198 million yuan, compared to a profit of 127 million yuan in the previous year, reflecting a decrease of 255.99% [1][2] - The net cash flow from operating activities was 489 million yuan, an increase of 242.40% compared to the previous year [1][2] Financial Performance - For the first quarter of 2025, the company reported total operating revenue of 2.38 billion yuan, a decline of 2.48% year-on-year [3] - The net profit attributable to shareholders for the first quarter was 25.62 million yuan, a year-on-year increase of 143.85% [3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 23.26 million yuan, up 144.60% from the previous year [3] - The net cash flow from operating activities for the first quarter was 88.36 million yuan, an increase of 17.52% compared to the same period last year [3] Capital Raising - The company raised a total of 359.18 million yuan from its initial public offering, with a net amount of 299.37 million yuan after deducting issuance costs [4] - The final net amount raised was 26.05 million yuan less than the original plan of 559.87 million yuan [4] - The company has raised a total of 1.16 billion yuan since its listing [6]

特此公告。 漱玉平民大药房连锁股份有限公司 董 事 会 2025 年 5 月 13 日 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，漱玉平民大药房连锁股份有限公司（以下简称"公 司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现将相关事项公告如下： 本 次 活 动 将 采 用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 录 " 全 景 路 演 " 网 站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP，参 与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。届时公司高管将在 线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持续 发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ | 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025- ...

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds, "Shuyu Convertible Bonds," despite meeting the conditions for a downward adjustment, reflecting confidence in its long-term development and market position [1][7]. Group 1: Convertible Bond Details - The company issued 8 million convertible bonds with a total value of 800 million RMB, each with a face value of 100 RMB, approved by the China Securities Regulatory Commission [1][2]. - The initial conversion price was set at 21.27 RMB per share, with the conversion period running from June 21, 2023, to December 14, 2028 [2]. - The conversion price was adjusted from 15.00 RMB to 14.95 RMB per share effective from July 16, 2024, following the annual shareholders' meeting [4]. Group 2: Price Adjustment Conditions - The company’s board has the authority to propose a downward adjustment of the conversion price if the stock price falls below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [6]. - The adjustment requires approval from two-thirds of the voting rights at the shareholders' meeting, with bondholders required to abstain from voting [6]. Group 3: Recent Decisions - As of May 12, 2025, the stock price conditions for a downward adjustment were met, but the board decided not to propose a price reduction, maintaining the current conversion price [7]. - The board will reassess the situation after June 12, 2025, should the conditions for a downward adjustment be triggered again [7].

关于不向下修正"漱玉转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： | 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-042 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 1、截至 2025 年 5 月 12 日，漱玉平民大药房连锁股份有限公司（以下简称"公司"） 股票已出现任意连续三十个交易日中至少有十五个交易日的收盘价格低于当期转股价格的 85%的情形，触发"漱玉转债"转股价格向下修正条件。 2、2025 年 5 月 12 日，公司召开第四届董事会第六次会议，审议通过了《关于不向下 修正"漱玉转债"转股价格的议案》，公司董事会决定本次不向下修正"漱玉转债"转股价 格，同时自本次董事会审议通过次一交易日起未来一个月内（即 2025 年 5 月 13 日至 2025 年 6 月 12 日），如再次触发"漱玉转债"转股价格向下修正条件，亦不提出向下修正方案。 在此期间之后（从 2025 年 6 月 13 日重新起 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-041 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 漱玉平民大药房连锁股份有限公司（以下简称"公司"）第四届董事会第六次会议于 2025 年 5 月 12 日在公司会议室以现场结合通讯表决方式召开。会议通知已于 2025 年 5 月 12 日以书面、电子邮件等方式送达各位董事，本次会议为紧急临时会议，根据《公司章程》 相关规定，董事长在本次会议上就紧急召开本次会议的情况进行了说明，公司全体董事均 同意豁免本次董事会会议的通知时限要求。会议应到董事 9 人，实到董事 9 人，其中董事 杨策先生，独立董事赵振基先生、晏莉女士、李文明先生以通讯表决方式出席。公司监事和 高级管理人员列席了本次会议。会议由董事长李文杰先生主持，本次会议召开符合《中华人 民共和国公司法》及《公司章程》等有关规定。 日重 ...

Core Insights - The chain pharmacy industry in 2024 is experiencing a significant slowdown, transitioning from a rapid expansion phase to one of reduced growth and declining profitability [2][3] - Six major private chain pharmacies reported revenue growth of less than 10%, with the highest being 8.01%, a stark contrast to previous years where many exceeded 20% [2] - Only Yifeng Pharmacy managed to achieve net profit growth, while the other five companies faced varying degrees of decline [2][5] Revenue and Profitability - Yifeng Pharmacy reported a revenue of 24.062 billion yuan with a net profit growth of 8.26%, becoming the only company to grow in a challenging environment [5] - Dazhenlin achieved the highest revenue of 26.497 billion yuan but saw a net profit decline of over 20% [5] - Laobaixing maintained a sales figure of 22.357 billion yuan, but its profits nearly halved [5] - Regional players like Shuyupingmin reported a loss of nearly 200 million yuan, while Jianzhijia's profits plummeted by about 70% [5] Store Expansion and Closure - Despite the overall industry challenges, the number of stores for major chain pharmacies continued to grow, with Dazhenlin adding 2,479 stores, Yifeng adding 1,434, and Laobaixing adding 1,703 [7] - The total number of closed pharmacies reached 25,114 in the first three quarters of 2024, with a growing trend in closures [5][6] Industry Challenges - The industry faces significant pressures from tightened healthcare policies, increased online competition, and changing consumer spending habits [3][8] - The competitive landscape has intensified, leading to price wars and promotional battles that compress profit margins [8] - Regulatory changes, such as stricter healthcare cost controls and increased compliance requirements, have further strained profitability [8][10] Strategic Responses - Companies are focusing on digital transformation and optimizing business structures to enhance efficiency and customer service [12] - Diversification into health products, beauty items, and health management services is becoming a strategic priority [12] - The integration of online and offline sales and services is seen as essential for future success, although it requires significant investment [12]

特别提示： | 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-040 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 董 事 会 2025 年 5 月 8 日 漱玉平民大药房连锁股份有限公司（以下简称"公司"）《2024 年年度报告》及摘要已 于 2025 年 4 月 29 日在巨潮资讯网（http://www.cninfo.com.cn）上披露。为了便于投资 者进一步了解公司 2024 年度经营情况，公司将于 2025 年 5 月 16 日（星期五）16:00-17:00 举行 2024 年度网上业绩说明会。本次年度业绩说明将通过深圳证券交易所提供的"互动易" 平台举行，投资者可登录"互动易"网站（http://irm.cninfo.com.cn），进入"云访谈" 栏目参与本次年度业绩说明会。 出席本次业绩说明会的人员有：董事长李文杰先生，董事兼总裁秦 ...

A股医药商业板块异动拉升，嘉事堂封板涨停，瑞康医药、润达医疗、漱玉平民、合富中国、海王生物 等跟涨。 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-039 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 5、根据《漱玉平民大药房连锁股份有限公司创业板向不特定对象发行可转换公司债券 募集说明书》（以下简称"《募集说明书》"）中相关约定："在本次发行的可转换公司债 券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价低于当 期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交公司股东大会表 决。" 截至本公告日，漱玉平民大药房连锁股份有限公司（以下简称"公司"）股票自 2025 年 4 月 17 日至 2025 年 4 月 30 日已有 10 个交易日的收盘价格低于当期转股价格的 85%（即 12.71 元/股）的情形，预计可能触发"漱玉转债"转股价格向下修正条件。若触发转股价 格修正条件，公司将按照 ...